Hemispherx Biopharma Inc., of Philadelphia, said it completed its technology transfer of the Ampligen manufacturing processes to Avrio Biopharmaceuticals LLC, of Irvine, Calif. The transfer consists of providing Avrio with all information that is relevant to the manufacturing process of Ampligen and associated assays. The first cGMP lot is expected to be compounded, filled and finished in November and released in December for use in the company’s early access program in Europe and Turkey.